# Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Source: https://onco.cc/trials/nct07259317/  
OnCo record `nct07259317` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Relacorilant and Gemcitabine in pancreatic ductal adenocarcinoma, run by Corcept Therapeutics, now recruiting.

## Summary

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 2 interventional study registered as NCT07259317 by Corcept Therapeutics, with 80 participants planned, started 2026-01-27 and due to reach its primary completion in 2027-09. Interventions recorded: Relacorilant, Nab-paclitaxel and Gemcitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07259317
- Phase: 2
- Setting: A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)
- Sponsor: Corcept Therapeutics
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07259317: https://clinicaltrials.gov/study/NCT07259317

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Relacorilant](https://onco.cc/drugs/relacorilant/)
- companies: [Corcept Therapeutics](https://onco.cc/companies/corcept/)

---
JSON: https://onco.cc/api/v1/entities/nct07259317.json